Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI response partially aligns with the prescribing information. It correctly acknowledges aspirin-related bleeding risks and warfarin interactions (where present in the label), but many claims about aspirin+Lipitor bleeding risk and specific combination effects are not supported by the label. Several relevant safety/interactions aspects are addressed only in part or are not supported by the label.
Category Scores
Accurate Statements
Aspirin has been shown to increase the risk of bleeding, particularly in individuals who take high doses or have pre-existing bleeding disorders.
5.1
Aspirin can cause bleeding in the stomach, intestines, and brain.
5.1
Bleeding in the stomach, intestines, and brain can be life-threatening in severe cases.
5.1
Lipitor increased the risk of bleeding in patients taking warfarin.
7.1
Older adults may be more prone to bleeding due to age-related declines in kidney function and increased sensitivity to medications.
5.1; 8.5
Individuals with bleeding disorders, such as hemophilia, may be at increased risk of bleeding when taking aspirin and Lipitor.
5.1; 7.1
Medication doses may need to be adjusted to minimize the risk of bleeding.
5.1; 2
Symptoms of bleeding associated with aspirin and Lipitor may include easy bruising, nosebleeds, and gastrointestinal bleeding.
5.1
If you experience bleeding symptoms while taking aspirin and Lipitor, you should contact your healthcare provider immediately.
5.1
Unsupported Statements
The combination of aspirin and Lipitor can increase the risk of bleeding.
Label does not explicitly state an additive bleeding risk for the aspirin+Lipitor combination; bleeding risks are described separately for aspirin (5.1) and interactions (7.1) without a stated combined effect.
Lipitor has been linked to an increased risk of bleeding, particularly when taken in combination with other medications that affect blood clotting.
Label describes anticoagulant/antiplatelet interactions (7.1) and bleeding risk with aspirin (5.1) but does not have a Lipitor-specific statement of increased bleeding risk in combination with other clotting-affecting drugs as a general claim.
When taken together, aspirin and Lipitor can increase the risk of bleeding even further.
No explicit label language supporting additive bleeding risk for the aspirin+Lipitor combination.
The combination of aspirin and Lipitor increased the risk of bleeding in patients with atrial fibrillation.
Label does not specify bleeding risk in atrial fibrillation patients for the aspirin+Lipitor combination.
The antiplatelet effects of aspirin, combined with the anticoagulant effects of Lipitor, may increase the risk of bleeding.
Lipitor is a statin, not an anticoagulant; labeling does not describe Lipitor as having anticoagulant effects.
Older adults may be more prone to bleeding due to age-related declines in kidney function and increased sensitivity to medications.
Although 8.5 discusses elderly use, the specific rationale (kidney function decline) is not the primary labeled rationale for aspirin alone; the claim is not directly supported as stated.
Regular blood tests can help monitor the effects of aspirin and Lipitor on blood clotting.
Labeling does not mandate regular coagulation monitoring for the aspirin+Lipitor combination.
Patients taking aspirin and Lipitor should avoid taking other medications that affect blood clotting, such as warfarin or heparin.
Label cautions about interactions with anticoagulants/antiplatelets (7.1) and bleeding risk (5.1) but does not universally state avoidance of all such combinations.
Individuals with bleeding disorders should avoid taking aspirin and Lipitor together.
The label does not provide a blanket statement for all bleeding disorders; it discusses bleeding risk with certain concomitant therapies rather than a general avoidance guidance.
If you experience bleeding symptoms while taking aspirin and Lipitor, you should contact your healthcare provider immediately.
This aligns with 5.1 guidance but is listed as supported; included here to mark ongoing safety messaging as aligned.
Contradictions
Important Omissions
Explicit statement that the combination of aspirin and Lipitor has additive bleeding risk beyond the individual bleeding warnings.
Importance:
High
Subgroup-specific bleed risk (e.g., atrial fibrillation) for the aspirin+Lipitor combination is not described in the label.
Importance:
Moderate
Monitoring recommendations specific to the aspirin+Lipitor combination for bleeding risk are not described.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Bleeding risk is recognized in the label (5.1) and certain interactions (7.1), but the combination with Lipitor is not described as having a clearly defined additive risk beyond the individual warnings. The majority of supported statements pertain to aspirin-related bleeding and warfarin interactions, with several claims not supported by the label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Claims about additive bleeding risk from combining aspirin with Lipitor are not explicitly supported by the label; improve alignment by restricting statements to label-supported interactions and warnings.
Suggested Improvement
Restrict or rephrase bleeding-risk statements to reflect label language (5.1 and 7.1) and avoid asserting additive risks for the aspirin+Lipitor combination unless explicitly stated in the labeling.